Sonoma Pharmaceuticals (SNOA) Cost of Revenue (2010 - 2026)

Sonoma Pharmaceuticals has reported Cost of Revenue for 17 years, with the latest figure at $3.8 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 50.1% year-over-year to $3.8 million in Q2 2026; TTM through Jun 2026 was $13.4 million, a 44.17% increase from a year earlier, with the FY2026 full-year figure at $12.1 million, up 37.3% from the prior year.
• Cost of Revenue was $3.8 million for Q2 2026 at Sonoma Pharmaceuticals, up from $3.4 million in the prior quarter.
• The five-year high for Cost of Revenue was $3.8 million in Q2 2026, with the low at $1.7 million in Q4 2023.
• Average Cost of Revenue over 5 years is $2.4 million, with a median of $2.2 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue decreased 28.29% in 2022, then jumped 57.08% in 2025.
• Over 5 years, Cost of Revenue stood at $2.1 million in 2022, then decreased by 20.59% to $1.7 million in 2023, then jumped by 36.71% to $2.3 million in 2024, then grew by 17.65% to $2.7 million in 2025, then jumped by 41.87% to $3.8 million in 2026.
• The last three Cost of Revenue figures came in at $3.8 million (Q2 2026), $3.4 million (Q1 2026), and $2.7 million (Q4 2025), per Business Quant data.